Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
BMC Cancer|December 20, 2014
Distinctive outcome in patients with non-uterine and uterine leiomyosarcomaWolfgang Lamm, Camilla Natter, Sophie Schur, et al.
BMC Cancer|April 18, 2015
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trialThomas Brodowicz, Bernadette Liegl-Atzwager, Emmanuelle Tresch, et al.
Pathology|December 25, 2019
Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrumIva Brčić, Thomas Brodowicz, Lorenzo Cerroni, et al.
International Journal of Surgery (London, England)|September 4, 2013
Surgical treatment of GIST--an institutional experience of a high-volume centerKatrin Schwameis, Alexandra Fochtmann, Michael Schwameis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 30, 2020
Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusionsIva Brčić, Theresa Maria Godschachner, Marko Bergovec, et al.
Cancers|April 3, 2021
Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, et al.
The International Journal of Artificial Organs|December 21, 2011
Whole body hyperthermia by extracorporeal circulation in spontaneously breathing sarcoma patients: hemodynamics and oxygen metabolismGottfried J Locker, Eva-Maria Fuchs, Nina Worel, et al.
Cancers|December 16, 2020
Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC StudyThomas Brodowicz, Bernadette Liegl-Atzwanger, Nicolas Penel, et al.
Clinical Colorectal Cancer|February 11, 2015
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 StudyKlaus Kaczirek, Tudor E Ciuleanu, Damir Vrbanec, et al.
Anti-Cancer Drugs|March 24, 2012
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysisDominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, et al.
Pageof 9